JP6535008B2 - ナノ粒子を含む医薬組成物、その調製及び使用 - Google Patents

ナノ粒子を含む医薬組成物、その調製及び使用 Download PDF

Info

Publication number
JP6535008B2
JP6535008B2 JP2016541402A JP2016541402A JP6535008B2 JP 6535008 B2 JP6535008 B2 JP 6535008B2 JP 2016541402 A JP2016541402 A JP 2016541402A JP 2016541402 A JP2016541402 A JP 2016541402A JP 6535008 B2 JP6535008 B2 JP 6535008B2
Authority
JP
Japan
Prior art keywords
nanoparticles
nanoparticle
biocompatible
pharmaceutical composition
nanoparticle aggregates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016541402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504603A (ja
Inventor
ポティエ,アニエス
レヴィ,ローラン
ジェルマン,マチュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanobiotix SA
Original Assignee
Nanobiotix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix SA filed Critical Nanobiotix SA
Publication of JP2017504603A publication Critical patent/JP2017504603A/ja
Application granted granted Critical
Publication of JP6535008B2 publication Critical patent/JP6535008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/242Gold; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/244Lanthanides; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1098Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Ceramic Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016541402A 2013-12-20 2014-12-19 ナノ粒子を含む医薬組成物、その調製及び使用 Active JP6535008B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306799.1 2013-12-20
EP13306799.1A EP2886128A1 (de) 2013-12-20 2013-12-20 Pharmazeutische Zusammensetzung mit Nanopartikeln sowie ihre Herstellung und Verwendungen
PCT/EP2014/078619 WO2015091888A1 (en) 2013-12-20 2014-12-19 Pharmaceutical composition comprising nanoparticles, preparation and uses thereof

Publications (2)

Publication Number Publication Date
JP2017504603A JP2017504603A (ja) 2017-02-09
JP6535008B2 true JP6535008B2 (ja) 2019-06-26

Family

ID=49955847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016541402A Active JP6535008B2 (ja) 2013-12-20 2014-12-19 ナノ粒子を含む医薬組成物、その調製及び使用

Country Status (4)

Country Link
US (1) US10265406B2 (de)
EP (2) EP2886128A1 (de)
JP (1) JP6535008B2 (de)
WO (1) WO2015091888A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029635B1 (ru) 2011-12-16 2018-04-30 Нанобиотикс Применение наночастицы, включающей металлический материал, покрытый материалом оксида гафния, в онкологии и композиция, ее содержащая
WO2014191569A1 (en) 2013-05-30 2014-12-04 Nanobiotix Pharmaceutical composition, preparation and uses thereof
ES2774365T3 (es) 2014-11-25 2020-07-20 Curadigm Sas Composición farmacéutica, preparación y usos de la misma
UA123665C2 (uk) 2014-11-25 2021-05-12 Кюрадігм Сас Фармацевтична композиція, її одержання і застосування
EP3229776B1 (de) 2014-11-25 2023-06-28 Curadigm Sas Pharmazeutische zusammensetzung mit kombination von mindestens zwei verschiedenen nanoteilchen und pharmazeutische zusammensetzung, herstellung und verwendungen
EP3223796B1 (de) 2014-11-25 2021-07-21 Curadigm Sas Pharmazeutische zusammensetzung, herstellung und verwendungen davon
UA124572C2 (uk) 2015-05-28 2021-10-13 Нанобіотікс Наночастинки для застосування як терапевтичної вакцини
ES2664584B2 (es) * 2016-09-19 2018-12-13 Universidade De Santiago De Compostela Nanoparticulas con interiores protegidos, y métodos de uso de las mismas
JP7469107B2 (ja) * 2020-03-31 2024-04-16 株式会社アルバック 金ナノ粒子の凝集体、金ナノ粒子分散液、放射線治療用増感剤及び金ナノ粒子分散液の製造方法
KR20230038659A (ko) * 2020-05-26 2023-03-21 나노비오띡스 나노 입자, 전리 방사선 및 그의 혁신적인 치료용 조합
CN112957469A (zh) * 2021-02-26 2021-06-15 广东药科大学 pH响应性磁性纳米核壳载药体系及其构建方法和应用
WO2026074471A1 (en) 2024-10-02 2026-04-09 Janssen Pharmaceutica Nv Combination therapies with hafnium oxide nanoparticles and pd-l1 antibodies for use in the treatment of non small cell lung cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645464B1 (en) * 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
IL181126A0 (en) 2006-11-01 2007-07-04 S B Biotechnologies Ltd Preparation of gold-containing nano-liposome particles and their use in medical therapy
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
DE102008003615A1 (de) 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
EP2130553A1 (de) 2008-06-05 2009-12-09 Nanobiotix Anorganische Nanopartikel mit hoher Dichte, um in-vivo Zellen zu zerstören
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US8580312B2 (en) * 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
WO2011133228A2 (en) 2010-04-23 2011-10-27 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
US20130177523A1 (en) * 2010-07-13 2013-07-11 University Of Utah Research Foundation Gold particles and methods of making and using the same in cancer treatment
AR094577A1 (es) * 2013-01-25 2015-08-12 Nanobiotix Composiciones para el tratamiento de cáncer, preparación y usos de las mismas

Also Published As

Publication number Publication date
WO2015091888A1 (en) 2015-06-25
US20160310614A1 (en) 2016-10-27
EP2886128A1 (de) 2015-06-24
EP3082864A1 (de) 2016-10-26
JP2017504603A (ja) 2017-02-09
US10265406B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
JP6535008B2 (ja) ナノ粒子を含む医薬組成物、その調製及び使用
US8845507B2 (en) Inorganic nanoparticles of high density to destroy cells in-vivo
JP6042450B2 (ja) 金属材料および酸化ハフニウム材料を含むナノ粒子、その製造および使用
JP6619231B2 (ja) 癌を治療するための電離放射線との併用での無機ナノ粒子組成物
US9700621B2 (en) Metallic nanoparticles, preparation and uses thereof
NZ625848B2 (en) Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190530

R150 Certificate of patent or registration of utility model

Ref document number: 6535008

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250